Nucleosides analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2153-2159

  Drusano, G L ^a   D'Argenio, D Z ^b   Symonds, W ^c   Bilello, P A ^a   McDowell, J ^c   Sadler, B ^c   Bye, A ^c   Bilello, J A ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b University of Southern California ^*  (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALBUMIN; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOSIDE ANALOG; OROSOMUCOID; PLASMA PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; CARBAMIC ACID DERIVATIVE; SULFONAMIDE;

ARTICLE; CELL LINE; DRUG POTENTIATION; DRUG PROTEIN BINDING; FETAL CALF SERUM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; PRIORITY JOURNAL; DRUG EFFECT;

ANTI-HIV AGENTS; CARBAMATES; CELL LINE; DIDEOXYNUCLEOSIDES; DRUG SYNERGISM; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; SULFONAMIDES;

EID: 0031596029     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2153     Document Type: Article

References (9)

1. Bilello, J. A., P. A. Bilello, K. Stellrecht, J. Leonard, D. Norrbeck, D. J. Kempf, T. Robins, and G. L. Drusano. 1996. Human serum α1-acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:1491-1497.
2. D'Argenio, D. Z., and A. Schumitzky. 1990. ADAPT II: a program package for simulation identification and optimal experimental design. User's manual. Biomedical Simulations Resource, University of Southern California, Los Angeles.
3. Drusano, G. L., M. Prichard, P. A. Bilello, and J. A. Bilello. 1996. Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation. Antimicrob. Agents Chemother. 40:1143-1147.
4. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
5. Molla, A., M. Korneyeva, Q. Gao, S. Vasavasonda, P. J. Schipper, H. M. Mo, M. Marowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:270-276.
6. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
7. 3, abstr. 195. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections.
8. 3, abstr. LB7a. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. 3. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.